Clinical Trial: Can Neoadjuvant Chemoradiotherapy Be Ommited in Mid-rectal Cancer: a Prospective, Observational, Non-inferiority Trial

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823297) titled 'Can Neoadjuvant Chemoradiotherapy Be Ommited in Mid-rectal Cancer: a Prospective, Observational, Non-inferiority Trial' on Feb. 03.

Brief Summary: The goal of this observational study is to learn about the oncologic outcome of omitting neoadjuvant chemoradiotherapy in cT2N+ and cT3Nx mid-rectal cancer without mesorectal fascia involvement.

The main question it aims to answer is:

Does upfront total mesorectal excision result in non-inferior 3-year disease-free survival when compared to neoadjuvant chemoradiotherapy and total mesorectal excision in cT2N+ and cT3Nx mid-rectal cancer without mesorectal fascia involvement?

Participant...